Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verus' Childs' Play Brings in $98 Million A Round

This article was originally published in Start Up

Executive Summary

With a goal to focus on pediatric respiratory disease and allergy, several ex-Dura Pharmaceutical executives were able to attract $98 million in Series A funding without having technology, products, or IP. The company's June 2005 financing is another signal that investing in the highest-quality start-up biotechs is increasingly a game for VC firms with deep pockets.

You may also be interested in...



From Verus to Meritage: A Biotech Prototype for Tough Economic Times

Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.

From Verus to Meritage: A Biotech Prototype for Tough Economic Times

Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.

San Diego Still Shines Despite VC Setbacks

The San Diego life sciences industry has endured several losses or setbacks by local venture capital firms yet its start-ups remain top recipients of capital.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091135

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel